---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-051845"
form_type: "8-K"
ticker: "MED"
cik: "0000910329"
company_name: "MEDIFAST INC"
filed_at: "2026-08-03T20:12:19+00:00"
generated_at: "2026-08-03T20:13:08.439841+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Medifast Q2 2026 revenue $76.4M (-27.6% YoY), net loss $3.1M; guides Q3 rev $60-80M

## Summary
- Revenue $76.4M, down 27.6% YoY; net loss $3.1M ($0.28 loss per share) vs net income $2.5M ($0.22 EPS) in Q2 2025.
- Active earning coaches 11,700, down 48.7% YoY; revenue per active earning coach $6,529, up 41% YoY.
- Gross profit margin 69.9% vs 72.6% YoY; SG&A as % of revenue 75.6% vs 73.6%.
- Cash and investments $169.8M, no debt; working capital $160.5M.
- Q3 2026 revenue guidance $60-80M, loss per share $0.15-0.65; full year 2026 revenue $270-300M, loss per share $0.25-1.75.

## SEC filing metadata
- accession: 0001628280-26-051845
- form_type: 8-K
- ticker: MED
- cik: 0000910329
- company_name: MEDIFAST INC
- filed_at: 2026-08-03T20:12:19+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/910329/000162828026051845/0001628280-26-051845-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/910329/000162828026051845/med-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-051845
- JSON: https://secwatch.observer/filing/0001628280-26-051845.json
- Plain text: https://secwatch.observer/filing/0001628280-26-051845.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.